PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

VOLUME 46, 1993
SUBJECT AND AUTHOR INDEX

Pergamon Press
New York • Oxford • Seoul • Tokyo

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

US Editor-in-Chief

MATTHEW J. WAYNER

Division of Life Sciences, The University of Texas at San Antonio, San Antonio, TX 78249-0662

European Editor-in-Chief

SANDRA E. FILE

Psychopharmacology Research Unit, UMDS Division of Pharmacology, Guy's Hospital
P.O. Box 3448, London SE1 9QH, UK

Editorial Advisory Board

L. AHTEE, Helsinki, Finland
L. ALLIKMETS, Tartu, Estonia
ROBERT L. BALSTER, Richmond, VA
G. BIGGIO, Cagliari, Italy
M. BRILEY, Castres, France
ALLAN C. COLLINS, Boulder, CO
DONALD V. COSCINA, Toronto, Ontario, Canada
JACQUELINE N. CRAWLEY, Bethesda, MD
A. DOMENEY, Bradford, UK
ADRIAN J. DUNN, Shreveport, LA
BURR EICHELMAN, Philadelphia, PA
WILLIAM J. FREED, Washington, DC
RICHARD A. GLENNON, Richmond, VA
F. G. GRAEFF, São Paulo, Brazil
M. R. C. GREENWOOD, Davis, CA
ROLAND R. GRIFFITHS, Baltimore, MD
STEPHEN G. HOLTZMAN, Atlanta, GA
AKIRA HORITA, Seattle, WA
CHRIS E. JOHANSON, Baltimore, MD
HAROLD KALANT, Toronto, Ontario, Canada
G. JEAN KANT, Washington, DC
KATHLEEN M. KANTAK, Boston, MA
GEORGE F. KOOB, La Jolla, CA
CONAN KORNETSKY, Boston, MA
J. DAVID LEANDER, Indianapolis, IN
EMINY H. Y. LEE, Taipei, Taiwan
ALLEN S. LEVINE, Minneapolis, MN
WILLIAM J. McBRIDE, Indianapolis, IN
DONALD E. McMILLAN, Little Rock, AR
JACK H. MENDELSON, Belmont, MA
ROBERT D. MYERS, Greenville, NC
J. A. PRATT, Glasgow, UK
ROSARIO SAMANIN, Milan, Italy
HERMAN H. SAMSON, Winston-Salem, NC
PAUL R. SANBERG, Tampa, FL
PHIL J. SKOLNICK, Bethesda, MD
S. C. STANFORD, London, UK
M.-H. THIÉBOT, Paris, France
DEREK VAN DER KOOY, Toronto, Ontario, Canada
JEANNE M. WEHNER, Boulder, CO
BRUNO E. WILL, Strasbourg, France
J. C. WINTER, Buffalo, NY
ALICE M. YOUNG, Detroit, MI
IAN S. ZAGON, Hershey, PA

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

US Editorial Office:
Matthew J. Wayner
Division of Life Sciences, The University of Texas at San Antonio, 6900 North Loop 1604 West
San Antonio, TX 78249-0662
Fax: (210) 691-4510

European Editorial Office:
Sandra E. File
Psychopharmacology Research Unit, UMDS Division of Pharmacology, Guy's Hospital
P.O. Box 3448, London SE1 9QH, UK
Fax: 44-(0)71-955-4627

Production Editor:
Jonathan R. Goodnough
Pergamon Press, Tarrytown, NY 10591-5153

Publishing, Subscription, and Advertising Offices:
Pergamon Press Inc., 660 White Plains Road, Tarrytown, NY 10591-5153, USA, E-mail Address: ESUK.USA@ELSEVIER.COM; and Pergamon Press Ltd., Headington Hill Hall, Oxford OX3 0BW, UK

Published Monthly
Annual institutional subscription rate (1993): £785 (US$1256)
Sterling prices are definitive. US dollar prices are quoted for convenience only and are subject to exchange rate fluctuation. Prices include postage and insurance and are subject to change without notice.

Pharmacology Biochemistry and Behavior, Vol. 46, pp. III–VIII, 1993
Printed in the U.S.A. All rights reserved.

0091-3057/93 $6.00 + .00
Copyright © 1993 Pergamon Press Ltd.

SUBJECT INDEX

Acetylcholinesterase activity, 729
ACTH, 101
Activity, 243
Adaptation, 445
Addiction, 125
Adenylate cyclase, 289, 519
Adrenal medulla, 225
Adrenergic, 251
Affective disorder, 243
Aggression, 923
Aging, 27, 101, 405, 415, 799
Agonist, 759
Agonistic behavior, 67, 873
Agoraphobia, 715
Agoraphobia (thigmotaxis), 973
AH 6809, 383
Alcohol, 463, 985
Alcohol drinking, 365, 751
Alcohol-nonpreferring rats, 173, 631, 723
Alcohol-preferring rats, 173, 631, 723
Alcohol self-administration, 35
Alcohol withdrawal, 365
Allotetrahydrodeoxycorticosterone, 963
α-Adrenoceptors, 39
α_2-Adrenoceptor, 111
α-Ethyltryptamine (α-ET), 459
α-Lipoic acid, 799
α-Methyltryptamine (α-MeT), 459
α_2-Receptor, 117
Alprazolam, 89, 167
Amiloride, 83
AMPA receptors, 73, 703
AMPA/Kainate receptors, 881
Amperozide, 125
Amphetamine, 195, 459, 637, 653, 769, 819
Ampicillin, 361
Amygdala, 275
Analgesia, 145, 205
Analogs, 295
Angiotensin converting enzyme inhibitor, 751
Angiotensin II, 751
Animal model of depression, 215
A_9 nerve terminals, 973
Anorexia, 787
Antagonism, 237
Antagonist, 759
Antianalgesia, 331, 623
Antibiotics, 361
Anticonvulsant, 467
Antidepressants, 15, 423
Antiepileptogenic effect, 275
Antinociception, 295, 331
Anxiety, 569, 715, 897, 905, 967
Anxiolytic, 467
Anxiolytic effect, 647
Apomorphine, 135, 283, 587, 769
Appetite, 205
Appetite suppression, 653
Arterial blood pressure, 561
ATPase, 519
Attention, 415, 733
Autoanalgesia, 661
Autoradiography, 251, 631

Bacterial lipopolysaccharide, 787
Behavior, 51, 759, 769, 787, 959, 967
Behavioral activation, 581
Behavioral despair, 225
Behavioral disorganization, 51
Behavioral effects, 161
Behavioral facilitation, 397
Behavioral pharmacology, 435
Behavioral responses, 781
Behavioral stimulation, 553
Behavioural patterns, 709
Benzodiazepine(s), 167, 331, 661
Benzodiazepine receptors, 77, 161
β_2 adrenergic, 679
β-Adrenergic antagonists, 131
β-Adrenergic receptors, 77
β-Funaltrexamine, 813
Binding, 295
Blind humans, 45
Blinded rat pups, 609
Blood alcohol, 365
Blood glucose, 995
Blood pressure, 259
Body temperature, 967
Body weight, 209, 617
Bradykinin, 751
Bradykinin antagonist, 751
Brain, 125, 205
BRL 35135, 953
Bulimia nervosa, 679
Buspirone, 89, 569, 647, 905

Ca^{2+} channel antagonist, 365
Ca^{2+} channels, 365
Caffeine, 463, 733
Calcium, 553
Calmodulin, 697, 847
Cannabinoid, 575
Cannabis, 967
Carbohydrate suppression, 349
Carbon clearance test, 605
Carbon monoxide, 259
Castration, 309
Catalepsy, 135, 303
Catecholamine(s), 225, 251
Caudate-putamen, 251
CCK, 237
C57BL/6J mice, 35
CGS 10746B, 989
CGS 19755, 807
Chloramphenicol, 361
Chlordiazepoxide, 467
Chlorpromazine, 467
Chlorpyrifos, 219
Cholera toxin, 623
Cholinergic factors, 911
Cholinesterase, 219
Cholinesterase in RBC and tissues, 827
Chronic ethanol treatment, 27
Chronic treatment, 135
Cigarettes, 259
Circadian, 251
Circadian rhythm, 243, 609
Circadian rhythmicity, 45
Cl^- influx, 723
Clomipramine, 215
Clonazepam, 995
Clonidine, 39, 111, 265, 623
CNS, 631
Cocaine, 61, 125, 289, 703, 715, 835, 973, 989
Coffee drinking, 527
Cognition, 415, 799
Cognitive deficits, 889
Color and position discrimination, 733
Concurrent acute exercise, 827
Conditional interaction, 467
Conditioned avoidance, 759, 769
Conditioned avoidance responses, 673
Conditioned taste aversion(s), 153, 593
Conditioning, 149
Conflict, 905
Conflict test, 569
Corticosterone, 101
CPP, 807
Culture, 195
(±)Cyanopindolol, 349

D_1 receptor, 51
D_2 receptor, 51
DA reuptake, 709
DA turnover, 709
[D-Ala^2,NMePhe^4,Gly-ol]Enkephalin, 587
DALDA, 391
DAMGO, 391
d-Amphetamine, 153
Death, 61
d-Fenfluramine, 101, 349
Defensive burying paradigm, 897
Defensive withdrawal paradigm, 897
Delayed matching-to-sample, 733
Delta-9-tetrahydrocannabinol (Δ^9-THC), 295, 575
[D-Pen^2,L-Pen^5]Enkephalin, 587
(−)Deprenyl, 709

Depression, 225, 243, 667
Desipramine, 89
Development, 83, 637
Diazepam, 61, 89, 435, 569, 905
Diazepam capsule implants, 683
Diazepam dependence in rats, 683
Diazepam plasma levels, rats, 683
Discriminative stimulus effects, 989
Diurnal, 283
Dizocilpine, 423
DOI, 349
DOM, 459
Dopamine agonist(s), 51, 269, 703, 769
Dopamine antagonist, 769
Dopamine receptor(s), 769, 863
Dopamine receptor antagonist, 453
Dopamine uptake sites, 863
Dopamine, 21, 51, 101, 183, 195, 303, 405, 477, 543, 581, 715, 759, 769, 793, 867, 881, 943, 973
Dorsal immobility response, 841
Dorsal striatum (STr), 973
Dose–response curves, 149
Drinking, 125, 183
Drug discrimination, 963
Drug discrimination learning, 237, 593
Drug-induced side effects, 739
Drug-naive and drug-experienced mice, 905
Drug-taking behavior, 561
Dynorphin, 623
Dynorphin A-(1–13), 587
Dynorphin A(1–17), 331
Dynorphin antibody, 331
Dyskinesia, 427
Dystonia, 427

8-OH-DPAT, 141, 487
Elevated plus-maze test, 89
Enantiomeric forms, 15
Endogenous dopamine, 819
Endogenous opioids, 377, 483, 911
Endopeptidase 24.11, 777
Endotoxin, 787
Energy balance, 205, 617
Energy expenditure, 617
Energy substrate utilization, 617
Enkephalinase, 777
Entrainment, 609
Ephedrine, 411
Eserine, 729
Estradiol, 637, 673
Estrous cycle, 673
Ethanol, 35, 283, 309, 477, 519, 535, 661, 781
Ethanol preference, 853, 857
Ethological analysis, 67, 873
Excitatory amino acid, 617
Exploratory behavior, 101
Extrapyrimidal movement disorders, 793

Feeding, 487, 917, 967
Feeding and drinking, 787
Feeding behavior, 745
Fenfluramine, 653
Fentanyl, 315
Fentanyl induced, 265
5-HT receptor subtypes, 349
5-HT receptors, 125
5-HT_{1A} agonists, 569
5-HT_{1A} antagonist(s), 67, 873
5-HT_{1A} receptor(s), 141, 173, 289
5-HT_{1C} receptor, 289
5-HT_2 receptor, 289
5-HT_2 receptor antagonists, 857
5-HT_3 antagonist, 535
5-HTergic drugs, 427
5-Hydroxytryptamine, 487
Fixed ratio (FR), 667
Flumazenil, 161, 683
Flumazenil plasma levels, rats, 683
Flunarizine, 867
Fluoxetine, 933
Flupenthixol, 543
Food and water intake, 787
Food consumption, 209
Food intake, 205, 745, 933
Food reinforcement, 733
Forced swim(ming) test, 111, 215, 225
Formalin, 661
Foster mother, 609
Frontal cortex, 323
Furosemide, 473

G_s, 623
GABA, 477
GABA antagonist, 1
GABA receptors, 661
GABA transaminase inhibitor, 1
$GABA_A$, 897
$GABA_A$ benzodiazepine receptor, 723
$GABA_A$ receptor complex, 963
$GABA_A$ receptors, 77
$GABA_B$ receptors, 77
Gastric fistula, 683
Gastric transit, 411
Generalization, 593
Genetics, 511
Glutamate, 423
Glybenclamide, 205
Glyburide, 205
Grooming, 51, 673
Growth rate, 209
Guanine nucleotide binding or G-protein, 689

Habituation, 117
Habituation in the open field, 799
Haloperidol, 135, 195, 303, 323, 405, 739, 759, 847, 853
Heart rate, 259
Hedonic, 745
Heroin self-administration, 561
Hexobarbital, 73
Hibernation, 9
Hibernation trigger, 9
Hippocampus, 231, 689
Histamine, 95
Histamine H_3 receptor, 95
Homocysteic acid, 617
Horizontal movement, 269
Hormone, 897
HOT and COLD Mice, 519
Hot plate, 145
Hotplate test, 361
Housing conditions, 723
HPLC, 303
[^{3}H]Raclopride, 377
Human, 927
Human butyrylcholinesterase (HuBChE), 889
Human subjects, 781
Hyperalgesia, 661
Hyperlocomotion, 535
Hypermotility, 881
Hyperphagia, 679
Hyperthermia, 383
Hyperthyroidism, 729
Hypertonic saline intake, 473
Hypothalamus, 697
Hypothermia, 283, 309, 519, 729
Hypoxia, 867

ICI 118551, 953
ICS-205,930, 349
Idazoxan, 215, 265, 933
Idebenone, 415
Iloprost, 383
Imipramine, 423
Immobility, 295, 647
Immune system, 787
Immunity, 445
Immunomodulator, 787
Incremental repeated acquisition, 733
Indirect calorimetry, 617
Indorenate, 569
Inescapable stress, 231
Infection, 787
Influenza A PR8/34 virus, 167
Ingestion, 473
Ingestive behavior, 679
Inhibition, 219
Inositol phosphates, 323
Instrumental behavior, 943
Interaction, 73
Interleukin, 787
Interoceptive cues, 149
Intracerebroventricular administration, 787
Intranigral infusion, 427
Intrathecal naloxone, 331
Intraventricular, 21
In vitro, 819
In vivo electrochemistry (voltammetry), 715, 973
In vivo protection, 813
In vivo receptor binding, 377
Ion transport, 83
Ipsapirone, 569
Isoproterenol, 953
IV, 265

Kainic acid, 397
κ, 377
κ-Opiate receptors, 145
Ketanserin, 349
Ketanserin binding, 631
Kindling, 275

Learned helplessness, 231, 423
Learning, 553, 733, 799
Learning and memory, 959
Learning behavior, 867
Levodopa, 195
Lewis rat, 27
LHRH, 673
LHRH antagonism, 673
Lingual epithelium, 83
Lithium, 323
Locomotion, 51
Locomotor, 703
Locomotor activity, 95, 111, 135, 295, 341, 391, 587, 637, 989
Long-term effect, 867
Long-term potentiation, 847
Lordosis, 1
Lower lip retraction, 141
L-Triiodothyronine, 729

Macaca mulatta, 733
Macrophages, 605
Magnetic resonance imaging (MRI), 781
Magnetic resonance spectroscopy (MRS), 781
Male F344 rat, 101
Marijuana, 967
Marmoset, 21
Mast cell-deficient (W/W^v) mouse, 95
Matching-to-sample, 435
MDMA, 153, 439
Meal pattern, 787
Medial frontal cortex, 101
Medial prefrontal cortex, 51, 857
Melatonin, 45, 609
Memory, 799, 967
Mental performance, 463
Menthol, 259
Metabolism, 205, 617
Metergoline, 349
Methamphetamine, 135, 989
Methionine-enkephalin, 841
Methionine-enkephalin fragments, 841
Methylscopolamine, 435
Mice, 15, 111, 605, 989
Microdialysis, 341, 477, 581
Midazolam, 331, 605
Midbrain raphe nuclei, 487
MK-801, 15, 881
Modified forced swim test, 647
Molecular modeling, 295
Monoamines, 365, 933
Mood, 927
Morphine, 149, 205, 331, 341, 435, 473, 483, 623, 745, 995
Morris water maze, 889
Motivation, 581, 733, 943
Motor activity, 219
Motor control, 793, 943
Mouse, 587, 799, 835
MPTP, 739
MR 1452, 145
mRNA, 575
μ, 377
μ-Opiate, 519
μ-Opioid peptide agonists, 391
Muscarinic receptors, 219
Muscular rigidity, 265

N-*w*-nitro-L-arginine methyl ester, 959
Naloxone, 117, 145, 473, 917, 995
Naltrexone, 145, 653
NAN190, 141
NBQX, 73
Neostigmine, 435
Neostriatum, 943
Nervous system, 787
Neural graft, 225
Neuroimmunology, 787
Neuroimmunomodulation, 445
Neuropeptide Y, 543
Neuroreceptor, 251
Neurotoxicity, 739
Nicotine, 131, 135, 209, 283, 303
Nigrostriatal and mesolimbic DAergic system, 709
Nigrostriatum, 973
Nitric oxide, 959
Nitrous oxide, 161
Nitrous oxide, 927
NMDA antagonists, 15
NMDA receptor, 423, 807
N-methyl-D-aspartate (NMDA), 959
Nociception, 205
Noise, 35
Nongenomic, 1
Nonopioid, 117
Nor-binaltorphimine, 331, 813
Noradrenaline, 117, 411
Norepinephrine, 101, 225, 231
Norpseudoephedrine, 411
Novelty-induced hypoalgesia, 117
Nucleus accumbens, 341, 477, 581, 703, 857, 881, 943

Obese Zucker rats, 653
Obesity, 617
Olfactory bulbectomy, 77
Open-field behavior, 51
Operant behavior, 581, 733
Operant chambers, 315
Operant punishment paradigm, 905
Opiate(s), 237, 453, 917
Opiate antagonists, 593
Opiate or opioid, 689
Opioid analgesia, 777
Opioid drugs, 315
Opioid mediation, 373
Opioid(s), 117, 183, 473, 745, 819, 917
Oral movements, 427
Oral self-administration, 315
Organophosphate, 219
Orofacial movements, 405
Ovariectomy, 673
Oxotremorine, 729

Pain, 361, 661
Palatability, 745, 917
Panic disorders, 89
Paraventricular nucleus, 487, 933
Paraventricular nucleus of the hypothalamus (PVN), 617
Parkinsonism, 739
Pattern discrimination, 535
Pentobarbital, 661
Pentylenetetrazol, 467
Peptide YY, 679
Perinatal undernutrition, 89
Periodic mother deprivation, 609
Pertussin toxin, 689
PGE_2, 383
PGI_2, 383
Phagocytosis, 605
Phenelzine, 89
Phenylpropanolamine, 411
Phorbol ester binding, 553
Physostigmine, 435, 827
Picrotoxin, 661
Pigeon, 435
Pindolol, 141
(−)-Pindolol, 873
Pineal, 225
Pineal gland, 45
Pinobind 5-HT_{1A}, 67
PL017, 391
Place conditioning, 543
Pleasure, 527
Plus-maze, 467
Postnatal, 219
Postsynaptic, 51
Potentiation, 237
Prazosin, 61
Pre- and postweanling rats, 373
Precipitated abstinence, 683
Pregnanolone, 897
Premenstrual syndrome, 897
Preoptic, 251
Preoptic area, 39
Presynaptic, 51
Pretreatment, 889
Progesterone, 1, 897
Prolactin, 101
Prophylaxis, 889
Propranolol, 923
Protection, 889
Protein kinase C, 553
Pseudoephedrine, 411
Psychomotor performance, 927
Psychomotor stimulant, 453
Psychostimulant behavior, 715, 973
Puberty-accelerating pheromone, 835
Puffing behavior, 527

Quaternary metabolite, 739
Quinine, 315
Quinolinic acid, 303

Race, 259
(*R*)-α-Methylhistamine, 95
Rapid eye movement sleep deprivation, 863
Rapid smoking, 259
Rat(s), 21, 45, 51, 73, 117, 131, 141, 161, 209, 243, 251, 309, 383, 415, 427, 473, 483, 569, 617, 751, 787, 819, 863, 889, 897, 959, 989
Rat brain, 77
Rat fetus, 377
Rate of decarbamylation, 827
Reaction time, 463, 759, 769
Reactivity, 415
Rearing, 269
Receptor, 575, 759, 967
Recombinant strains, 511
Rectal temperature, 295
Reinforcement, 153, 183, 561
Reinforcer, 927
REM sleep, 215
REM sleep deprivation, 111
Reserpine, 405
Respiratory arrest, 61
Respiratory quotient, 617
Restricted feeding, 609
Reverse tolerance, 397
Review, 195
Reward, 183, 543, 917
Reward or reinforcement, 689
Risperidone, 853
Ritanserin, 349, 853, 857
Ro 15-1788, 661, 683
Rockland-Swiss mice, 923
Rodent, 967
Rotation-induced analgesia, 911

S20098, 45
Saccharin, 483
Salbutamol, 653
(*S*)-α-Fluoromethylhistidine, 95
Salt appetite, 473
Salt taste, 83
Sardinian alcohol-preferring rats, 853
SCH 23390, 759
Schedule-controlled behavior, 435
SCN, 251
Scopolamine, 215, 219, 435
Screening models, 15
SDZ 216-525, 873

Sedation, 967
Seizures, 61, 365, 467
Selected lines, 519
Self-administration, 125, 689
Self-stimulation, 453
Sensitization, 341
Septum, 251
Serotonin, 9, 21, 101, 125, 225, 289, 365, 477, 569, 715, 923, 973
Serotonin *N*-acetyltransferase rhythm, 609
Serotonin-2 receptors, 631
7-Chlorokynurenic acid, 275
Sex and age differences, 985
Sex differences, 637, 777
Sexual behavior, 1, 215
Sexual conduct, 697
Sexual differentiation, 637
Shock intensity, 569
Short-term memory, 733
6-Hydroxydopamine, 397
SK&F38393, 269
SK&F77434, 269
SK&F82958, 269
Skinner box, 667
Sleep disorders, 45
Sleeping time, 73
SM-3997, 647
Smoking, 527
Social behavior, 67, 873
Social interaction, 161
Soman, 889
Spatial learning, 27, 415
Spiperone, 759
Stearate microelectrode, 973
Stereotyped behavior, 135
Stereotypic behavior, 51
Stereotypy, 637
Stereotypy behavior, 269
Steroid, 1
Straw suspension, 647
Straw-climbing behavior, 647
Stress, 35, 101, 167, 315, 445, 511, 605
Stress-induced analgesia, 777
Stress-induced antinociception, 373
Striatum, 195, 303, 323, 341, 819, 863, 867
Structure–activity relationship, 295
Strychnine-insensitive glycine receptors, 275
Subcellular distribution, 553
Subjective effects, 927
Substantia nigra, 427
Supersensitivity, 397
Suprachiasmatic, 251
Swimming activity, 111

Tail electric stimulation test, 373
Tail-flick, 149
Tail-tremor, 131
Tardive dyskinesia, 739
Target biting, 923
Taste, 745
Temperature, 483, 953
Temporal discrimination learning, 27
Temporal response differentiation, 733
Terbutaline, 679
Testosterone, 637, 835
Thermal balance, 953
Thermogenesis, 617
Thermoregulatory behavior, 953
Thigmotaxis, 269
Thioctic acid, 799
Thirst, 39
3α,5α-Tetrahydroprogesterone, 897
Thyroid, 243, 251
Thyroparathyroidectomy, 243, 251
Thyroxine, 243, 251
Time estimation, 733
Titration schedule, 435
Tolerance, 149, 283, 309, 341
Tourette's syndrome, 303
Transduction, 83
Tremor, 729
Trophic factor, 195
Tryptophan hydroxylase, 9

U 50-488, 145
Unpredictable electric shock, 667

Vacuous jaw movements, 793
Valproate, 323
Variable ratio, (VR), 667
Vasopressin, 309
Ventral tegmental area, 689, 857
Ventrolateral nucleus accumbens (vlNAcc), 715
Ventromedial hypothalamus (VMH), 251
Vervet monkeys, 985
Vestibular compensation, 807
Virus infection, 167

Water consumption, 209
Water deprivation, 315
Water intake, 39
Weight cycling, 209
Weight loss, 653
Withdrawal, 897

Xylamidine, 349

Yohimbine, 111

Zymosan test, 605

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 46 1993

AUTHOR INDEX

Abbott, F. V., 661
Ablordeppey, S. Y., 739
Abood, M. E., 575
Agmo, A., 183
Aguilar-Garcia, A., 215
Akarsu, E. S., 383
Albertson, T. E., 61
Allen, R. R., 733
Almeida, O. M. S., 729
Altenbaumer, M., 15
Alvares, K., 315
Amit, Z., 179
Andersen, S. L., 377
Andrén, P. E., 427
Anisman, H., 445, 511
Araki, Y., 131, 135
Armstrong, S. M., 45
Arts, K. S., 623
Asakura, W., 111
Ashani, Y., 889
Atrens, D. M., 153, 617
Axelrod, J., 967
Ayhan, I. H., 383

Babu, S. R., 827
Baeza, R., 673
Balboa, J. L., 167, 605
Bardo, M. T., 819
Baskin, P., 793
Bättig, K., 463, 527
Beauchemin, V., 77
Bell, R., 67, 873
Belmonte, A., 167, 605
Benavente, F., 673
Beninger, R. J., 543
Bergsträsser, E., 867
Berndt, C., 867
Berridge, K. C., 745
Bianchi, M., 145
Billington, C. J., 917
Björk, A., 125
Blokland, A., 27
Blundell, J. E., 349
Borkoski, J. P., 787
Borne, R. F., 739
Bowers, R. L., 483
Boyd, N. E., 205
Boyle, A. E., 179
Brandeis, R., 889
Braun, A. R., 51
Brock, J., 863
Broderick, P. A., 715, 973
Bryson, R., 35
Buffalo, E. A., 733
Buhrfiend, C. M., 195
Bunge, A., 463
Burgess, L. H., 101

Cabrera, T. M., 101
Cahill, D. W., 303
Callera, J. C., 39
Camargo, L. A. A., 39
Campbell, D. B., 101
Campos, M. F., 21
Canchola, E., 697
Carlisle, H. J., 953
Carpenter, C. L., 259
Carvey, P. M., 195
Caskey, N. H., 259
Cepeda-Benito, A., 149
Chae, Y.-L., 231
Chait, A., 361
Chakraborti, T. K., 219
Charalambous, A., 295
Chen, C.-J., 835
Chernet, E., 631
Chiu, T.-M., 781
Christie, M. J., 153
Cicala, G. A., 959
Ciccocioppo, R., 853, 857
Cimetiere, C., 361
Clor, K. M., 995
Coalson, D. W., 927
Cohen, E., 889
Cohen, S. A., 799
Coleman, C., 35
Compton, D. R., 295
Cordoba, N. E., 89
Corwin, R. L., 967
Coscina, D. V., 487
Cousins, M. S., 581, 943
Crain, S. M., 623
Crawley, J. N., 967
Cross, M. K., 101
Cullen, M. J., 415
Cumin, R., 905
Curtis, B. A., 161
Czech, D. A., 161

Dal Prá, G., 463
Dal Prá, P., 423
Dall, V., 73
Darlington, C. L., 807
Dawes, P., 117
de Beaurepaire, R., 361
De Cabo, C., 373
De Luca, L. A., Jr., 39
De Montis, M. G., 423
De Witte, P., 477
Dean, J. E., 209
DeBold, J. F., 1
Del Vecchio, R. A., 265
Dennis, T., 77
Derlet, R. W., 61
Deutsch, S. I., 963
Devane, W. A., 967
Diaz-Ruiz, O., 215
Díaz-Véliz, G., 673
Dobrosielski, M., 781
Dohrn, C. S., 927
Dorow, J., 519
Doyle, T. G., 745
Drucker, G. E., 195
Dube, S. N., 827
Dubuc, P. U., 953
Dussaubat, N., 673

El-Etri, M. M., 303
Emerich, D. F., 303
Eng, F., 715
Ervin, F. R., 985
Estall, L. B., 959

Falb, D. C., 483
Fan, F., 575
Farrar, J. D., 219
Federman, I., 183
Felder, C. C., 967
Feller, D. J., 519
Fernandez-Rial, J. C., 167
Fields, J. Z., 195
Fiorella, D., 289
Fischer, H. D., 867
Fitzgerald, A. L., 911
Flemming, D., 927
Fletcher, P. J., 487
Forgie, M. L., 637
Franklin, K. B. J., 661
Freire-Garabal, M., 167, 605
French, D., 989
Frye, C. A., 1
Fujimoto, J. M., 331, 623
Fukushima, T., 847
Furuno, K., 131, 135

Gallo, M. A., 897
Gambarana, C., 423
George, M., 101
Gillam, M. P., 733
Giraudo, S. Q., 917
Glennon, R. A., 459
Glick, S. D., 341
Gomita, Y., 131, 135
Gondoh, Y., 647
González-Bahillo, J., 605
Gordon, B. H., 101
Gosnell, B. A., 745
Grace, M. K., 917
Grady, D. R., 365
Grant, S. J., 959
Grigdesby, C. F., 911
Gross, J., 867
Gross, T. M., 259
Grunberg, N. E., 315
Grunwald, J., 889
Grupp, L. A., 751
Grzybowska, J., 295
Guardiola-Lemaitre, B., 45
Gunne, L. M., 427
Guzman-Flores, C., 985
Gyarmati, S., 709

Haefely, W., 553
Hagan, M. M., 679
Hamdi, A., 863
Hampe, S., 15
Handa, R. J., 101
Hara, C., 667
Harding, S., 751
Hársing, G. L., 709
Hartmann, H., 799
Hasenfratz, M., 463, 527
Hata, N., 101
Heidbreder, C., 477
Hill, L. J., 125
Hobson, H., 67, 873
Hodges, B. L., 161
Holtzman, S. G., 813
Hong, E., 569
Hubbell, C. L., 473
Hudzik, T. J., 435
Hull, K. M., 411
Huston-Lyons, D., 453

Innes, D. G. L., 777

Jackson, D. M., 153
Jacober, A., 527
Janowsky, D., 365
Jarvik, M. E., 259
Jaskiw, G. E., 51
Jenck, F., 905
Jibiki, I., 847
Johnson, A. E., 427
Johnson, D. W., 341
Johnson, R. G., 289
Jones, E. A., 125
Josselyn, S. A., 543
Juarez, J., 985

Kaddis, F. G., 703
Kameyama, T., 587
Kato, Y., 609
Kavaliers, M., 777
Kehoe, P., 377
Kirch, D. G., 323
Kiyatkin, E. A., 561
Klein, L. C., 315
Klug, J. M., 397
Knoll, J., 709
Kolachana, B. S., 51
Kolta, M. G., 819
Kornak, E. P., Jr., 715

Kornetsky, C., 453
Kramer, G., 231
Kubota, T., 847
Kulikov, A. V., 9
Kurokawa, K., 847

Laino, C. H., 89
Lauchlan, C. L., 243
Lavoie, N., 77
Lawton, C. L., 349
Leibowitz, S. F., 933
Levine, A. S., 917
Li, R., 323
Li, T.-K., 173, 631, 723
Lichtor, J. L., 927
Liminga, U., 427
Lin, D., 195
Lin, H. Q., 153
Lin, S., 295
Lo, E. S., 195
Lorens, S. A., 101
Lukas, S. E., 781
Lumeng, L., 173, 631, 723
Lun, A., 867

Maeyama, K., 95
Maher, T. J., 411
Maickel, R. P., 911
Maillefer, R. H., 161
Makriyannis, A., 295
Marciniak, G., 295
Martin, B. R., 295, 575
Martin, J. R., 553, 905
Martín, M. I., 373
Martin, W. R., 683
Massi, M., 853, 857
Mastropaolo, J., 963
Matray-Devoti, J., 923
Matsumoto, K., 111
Mayfield, R. D., 759, 769
McBride, W. J., 631, 723
McCarthy, W. J., 259
McCullough, L. D., 581
McCutcheon, N. B., 473
McEachron, D. L., 243, 251
McGivern, R. F., 309
McGonigle, P., 251
McGregor, I. S., 153
McMillen, B. A., 125
McNulty, O. M., 45
Melcer, T., 309
Melchior, C. L., 309
Meloni, D., 423
Melton, P. M., 237
Menani, J. V., 39
Mendelson, J. H., 781
Menéndez, J. A., 617
Meneses, A., 569
Mermelstein, P. G., 1
Meyer, Melissa E., 391
Meyer, Merle E., 269, 391, 841
Midgley, D. E., 243
Mierson, S., 83
Mizinga, K. M., 283
Mollenauer, S., 35
Molthen, R. C., 251
Moore, N. A., 141
Mora, S., 673
Moreau, J.-L., 905
Morimoto, K., 275
Moss, D. E., 679
Müller, W. E., 799
Myers, R. D., 125

Najim, R. A., 995
Namba, T., 275
Narayanan, S., 881
Naruo, T., 667
Navarro, V., 183
Nicastle, L. D., 483
Nishimura, H., 647
Nordholm, L., 73
Norman, A. B., 303, 397
Nozoe, S.-I., 667
Núñez, M. J., 167, 605

O'Brien, R. A., 365
Ogawa, N., 667
Ohta, H., 111
Oliveira, M. P., 21
Onodera, K., 95
Ørntoft, U., 73
Orsingher, O. A., 89
Otsuki, S., 275

Padua, M., 183
Paez, X., 933
Palmour, R. M., 985
Panconi, E., 15
Panerai, A. E., 145
Panocka, I., 853, 857
Paronis, C. A., 813
Paule, M. G., 733
Pelleymounter, M. A., 415
Perrett, L., 141
Petty, F., 231
Plata-Salamán, C. R., 787
Polidori, C., 857
Pompei, P., 853
Pope, C. N., 219
Popova, N. K., 9
Porsolt, R. D., 15
Pournaghash, S., 593
Prasad, C., 863
Prickaerts, J., 27
Ptak, L. R., 195
Pucilowski, O., 365
Pujol, A., 373

Quock, R. M., 161

Raaijmakers, W., 27
Rabin, R. A., 289
Rabold, J. A., 631
Rady, J. J., 331
Rajachandran, L., 535
Randall, P. K., 759, 769
Raveh, L., 889
Redman, J. R., 45
Rees, G., 141
Reid, L. R., 173
Renzi, A., 39
Rezvani, A. H., 365
Riley, A. L., 237, 593
Roane, D. S., 205
Robertson, J. M., 751
Robinson, J. K., 967
Robinson, S. R., 377
Robison, M., 35
Rochford, J., 117
Rodríguez-Medina, M., 697
Rosado, A., 697
Rosenblatt, M. R., 259
Ross, K., 863
Roux, J., 15
Rushing, P. A., 209

Saad, W. A., 39
Sagen, J., 225
Sakai, N., 95
Salamone, J., 793
Salamone, J. D., 405, 581, 943
Sanberg, P. R., 303
Sanger, G., 141
Sansom, A. J., 807
Santos, R., 729
Sardo, J., 35
Sarkar, M., 453
Sauss, C., 575
Scheller, D., 867
Schmidt, A., 73
Schoch, P., 553
Segal, R., 179
Self, D. W., 689
Semus, S. F., 295
Settles, A. M., 83
Sexton, R. H., 51
Shaham, Y., 315
Shanks, N., 511
Shaw, W. N., 653
Shipley, M. T., 303
Shults, J. M., 269
Sloan, J. W., 683
Smith, B. R., 179
Smith, P. F., 807
Smith, S. S., 897
Smotherman, W. P., 377
Sokolowski, J. D., 943
Soliman, K. F. A., 283
Somani, S. M., 827
Sortwell, C. E., 225
Spear, L. P., 535
Spear, N. E., 535
Spieler, K., 553
Spirduso, W. W., 759, 769
Sprague, J. E., 911
Stein, E. A., 561
Stein, L., 689
Steinpreis, R. E., 405
Stewart, J., 637
Stock, M. J., 953
Stoll, S., 799
Stuart, J. F., 519
Suaudeau, C., 361
Suckow, M. A., 911
Suemaru, K., 131, 135
Sugishita, M., 609

Taddei, I., 423
Tagliamonte, A., 423
Takahashi, K., 609
Takashima, M., 609
Takeuchi, Y., 609
Tanaka, H., 667
Tanaka, M., 647
Taukulis, H. K., 467
Tekes, K., 709
Teoh, S. K., 781
Thielen, R. J., 723
Tiffany, S. T., 149
Tilton, C. L., 575
Timár, J., 709
Toyoshi, T., 587
Tseng, C.-C., 61
Tsuda, A., 647

Uetrecht, R. L., 911
Ukai, M., 587
Umphress, S. M., 377
Uretsky, N. J., 703, 881
Urresta, F., 673

Vandenbergh, J. G., 835
Velazquez, G., 183
Velazquez-Moctezuma, J., 215
Vergara-Onofre, M., 697
Vessotskie, J. M., 251
Viveros, M. P., 373
Vladar, K., 51
Voronova, I. P., 9

Waddell, A. B., 813
Wagner, G. C., 923
Wakita, S., 847
Wala, E. P., 683
Wallace, L. J., 703, 881
Ward, K. M., 377
Watanabe, H., 111
Watanabe, T., 95
Wechsler, R., 715
Weinberger, D. R., 51
Welch, C. C., 917
Wenger, G. R., 435
Wetzel, P. J., 161
Wilcox, R. E., 759, 769
Wilkins, D. R., II, 209
Williams, H. L., 125
Williams, R. L., 283
Willins, D. L., 881
Wilson, L., 231
Winders, S. E., 209
Wing, L. L., 323
Witkin, J. M., 989
Wong, D. T., 173
Woods, B. T., 781
Wright, D. W., 435
Wyatt, R. J., 323

Yamada, N., 275
Yamaguchi, N., 847
Yamauchi, T., 609
Yamazaki, S., 95
Yanai, K., 95

Zacny, J. P., 927
Zalcman, S., 445
Zanol, M. D., 303
Zanzillari, R., 411